ATE227583T1 - Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält - Google Patents

Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält

Info

Publication number
ATE227583T1
ATE227583T1 AT93902089T AT93902089T ATE227583T1 AT E227583 T1 ATE227583 T1 AT E227583T1 AT 93902089 T AT93902089 T AT 93902089T AT 93902089 T AT93902089 T AT 93902089T AT E227583 T1 ATE227583 T1 AT E227583T1
Authority
AT
Austria
Prior art keywords
histidine
growth hormone
pharmaceutical formulation
formulation containing
containing growth
Prior art date
Application number
AT93902089T
Other languages
English (en)
Inventor
Hans Holmegaard Soerensen
Lars Skriver
Annie Rassing Hoelgaard
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK204691A external-priority patent/DK204691D0/da
Priority claimed from DK136492A external-priority patent/DK136492D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE227583T1 publication Critical patent/ATE227583T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT93902089T 1991-12-20 1992-12-16 Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält ATE227583T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK204691A DK204691D0 (da) 1991-12-20 1991-12-20 Hidtil ukendt farmaceutisk praeparat
DK136492A DK136492D0 (da) 1992-11-10 1992-11-10 A pharmaceutical formulation
PCT/DK1992/000379 WO1993012812A1 (en) 1991-12-20 1992-12-16 A stabilized pharmaceutical formulation comprising growth hormone and histidine

Publications (1)

Publication Number Publication Date
ATE227583T1 true ATE227583T1 (de) 2002-11-15

Family

ID=26065653

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01128974T ATE368472T1 (de) 1991-12-20 1992-12-16 Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
AT93902089T ATE227583T1 (de) 1991-12-20 1992-12-16 Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01128974T ATE368472T1 (de) 1991-12-20 1992-12-16 Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält

Country Status (24)

Country Link
EP (2) EP0618807B1 (de)
JP (2) JP2950617B2 (de)
KR (1) KR100266502B1 (de)
AT (2) ATE368472T1 (de)
AU (1) AU667503B2 (de)
BG (1) BG63075B1 (de)
CA (1) CA2125855C (de)
CZ (1) CZ283361B6 (de)
DE (3) DE69232847T2 (de)
DK (1) DK0618807T3 (de)
ES (2) ES2185625T3 (de)
FI (1) FI115116B (de)
HU (1) HUT69402A (de)
IL (1) IL104152A (de)
MX (1) MX9207374A (de)
NL (1) NL300126I1 (de)
NO (1) NO942300L (de)
NZ (1) NZ246556A (de)
PT (1) PT618807E (de)
RO (1) RO111990B1 (de)
RU (1) RU2122426C1 (de)
SK (1) SK279641B6 (de)
UA (1) UA41502C2 (de)
WO (1) WO1993012812A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US5898030A (en) * 1994-06-17 1999-04-27 Applied Research Systems Ars Holding N.V hGH containing pharmaceutical compositions
TW426737B (en) * 1994-06-27 2001-03-21 Hayashibara Biochem Lab Saccharide composition with reduced reducibility, and preparation and uses thereof
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
EP0805689A1 (de) * 1995-01-13 1997-11-12 Novo Nordisk A/S Stabilisierte pharmazeutische zubereitung, welche ein wachstumshormon und x-lys enthält
ZA96122B (en) * 1995-01-13 1996-07-24 Novo Nordisk As A pharmaceutical formulation
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
US6936289B2 (en) 1995-06-07 2005-08-30 Danisco A/S Method of improving the properties of a flour dough, a flour dough improving composition and improved food products
ZA965367B (en) * 1995-07-12 1997-01-23 Novo Nordisk As A pharmaceutical formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
DE69835111T2 (de) 1997-04-09 2007-01-04 Danisco A/S Verwendung von Lipase zur Verbesserung von Teigen und Backwaren
JP2001522815A (ja) * 1997-11-12 2001-11-20 アルザ コーポレイション ポリペプチド類の自己会合を減少させる方法
WO1999055310A1 (en) * 1998-04-27 1999-11-04 Altus Biologics Inc. Stabilized protein crystals, formulations containing them and methods of making them
KR100890125B1 (ko) 2000-02-24 2009-03-24 일라이 릴리 앤드 캄파니 소마토트로핀의 지속적인 방출을 위한 비수성 주사제제들
AU2001271491A1 (en) 2000-06-26 2002-01-08 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
TWI283182B (en) 2000-08-07 2007-07-01 Nektar Therapeutics Inhalable spray dried 4-helix bundle protein powders having minimized aggregation
DK1314437T3 (da) 2000-08-11 2014-07-14 Chugai Pharmaceutical Co Ltd Stabiliserede antistofindeholdende præparater
NZ528260A (en) 2001-05-18 2005-09-30 Danisco Method of improving dough and bread quality with the addition of an enzyme that hydrolyses a glycolipid and a phospholipid and incapable of hydrolysing a triglyceride or monoglyceride
SG176314A1 (en) 2002-12-31 2011-12-29 Altus Pharmaceuticals Inc Human growth hormone crystals and methods for preparing them
BR0317896A (pt) * 2002-12-31 2005-12-06 Altus Pharmaceuticals Inc Complexos de cristais de proteìna e polìmeros iÈnicos
DE602004030000D1 (de) 2003-01-17 2010-12-23 Danisco Verfahren zur in-situ-herstellung eines emulgators in einem nahrungsmittel
WO2005012347A2 (en) 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
GB0405637D0 (en) 2004-03-12 2004-04-21 Danisco Protein
MX2007000626A (es) 2004-07-16 2007-03-07 Danisco Enzima lipolitica; usos de la misma en la industria alimenticia.
EP1827483B1 (de) * 2004-12-15 2014-07-02 Swedish Orphan Biovitrum AB (publ) Therapeutische formulierungen von keratinozyten-wachstumsfaktor
CN103520735B (zh) * 2004-12-22 2015-11-25 Ambrx公司 包含非天然编码的氨基酸的人生长激素配方
AU2006286486A1 (en) * 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
WO2007033427A1 (en) * 2005-09-23 2007-03-29 Metabolic Pharmaceuticals Limited Stabilisation of peptides with basic amino acids
PT1969004E (pt) 2005-12-28 2011-11-25 Novo Nordisk As Composições que compreendem uma insulina acilada e zinco e método para criar tais composições
MX2008016169A (es) 2006-07-07 2009-01-15 Novo Nordisk Healthcare Ag Nuevos conjugados de proteina y metodos para su preparacion.
WO2008076819A2 (en) * 2006-12-18 2008-06-26 Altus Pharmaceuticals Inc. Human growth hormone formulations
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
ES2607003T3 (es) 2008-10-30 2017-03-28 Novo Nordisk A/S Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria
HUE044381T2 (hu) * 2008-12-16 2019-10-28 Genzyme Corp Szintetikus intermedierek oligoszacharid-fehérje konjugátumok elõállításához
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
SG181769A1 (en) 2009-12-21 2012-07-30 Ambrx Inc Modified porcine somatotropin polypeptides and their uses
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
ES2566781T3 (es) * 2010-09-21 2016-04-15 Ferring B.V. Procedimiento mejorado para la producción de hormona del crecimiento humana recombinante
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
CN103415621A (zh) 2011-01-14 2013-11-27 雷德伍德生物科技股份有限公司 醛标记免疫球蛋白多肽及其使用方法
EP2854764B1 (de) 2012-06-05 2018-12-12 Neuroderm Ltd Zusammensetzungen mit apomorphin und organischen säuren und verwendungen davon
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US11559580B1 (en) * 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
CN108367094B (zh) * 2015-12-10 2021-09-14 株式会社目立康 肽组合物
EP3448885A4 (de) 2016-04-26 2020-01-08 R.P. Scherer Technologies, LLC Antikörperkonjugate und verfahren zur herstellung und verwendung davon
WO2019224842A1 (en) * 2018-05-25 2019-11-28 Dr. Reddy's Laboratories Ltd. Stable fusion protein formulation
KR20210024082A (ko) * 2018-06-25 2021-03-04 제이씨알 파마 가부시키가이샤 단백질 함유 수성 액제
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
IL281938B2 (en) 2018-10-26 2024-04-01 Novo Nordisk As Stable semaglutide compositions and uses thereof
CN114096269B (zh) 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂
WO2022197963A1 (en) * 2021-03-19 2022-09-22 Pfizer Inc. Long-acting growth hormone compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8504099D0 (en) 1985-02-18 1985-03-20 Wellcome Found Physiologically active substances
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
EP0374120A3 (de) * 1988-12-13 1991-07-31 Monsanto Company Zusammensetzung mit kontrollierter Wirkstoffabgabe von Polypeptiden
DK168790D0 (de) * 1990-07-13 1990-07-13 Novo Nordisk As

Also Published As

Publication number Publication date
DE69232847D1 (de) 2002-12-19
EP0618807A1 (de) 1994-10-12
HUT69402A (en) 1995-09-28
WO1993012812A1 (en) 1993-07-08
CZ150794A3 (en) 1995-01-18
RU2122426C1 (ru) 1998-11-27
UA41502C2 (uk) 2001-09-17
DE10399015I1 (de) 2012-05-03
BG63075B1 (bg) 2001-03-30
ES2291264T3 (es) 2008-03-01
EP1197222A3 (de) 2004-02-04
DE69232847T2 (de) 2003-09-11
FI942906L (fi) 1994-06-17
IL104152A (en) 1998-06-15
NZ246556A (en) 1996-03-26
PT618807E (pt) 2003-03-31
DE69233704D1 (de) 2007-09-13
JPH11315031A (ja) 1999-11-16
RU94045932A (ru) 1997-04-20
NO942300D0 (no) 1994-06-17
EP0618807B1 (de) 2002-11-13
RO111990B1 (ro) 1997-04-30
BG98806A (bg) 1995-02-28
NL300126I1 (nl) 2003-07-01
CA2125855A1 (en) 1993-07-08
JPH07502516A (ja) 1995-03-16
AU3344693A (en) 1993-07-28
CA2125855C (en) 2008-05-13
FI115116B (fi) 2005-03-15
DE69233704T2 (de) 2008-05-21
IL104152A0 (en) 1993-05-13
ATE368472T1 (de) 2007-08-15
DE10399015I2 (de) 2008-08-07
AU667503B2 (en) 1996-03-28
KR100266502B1 (ko) 2000-09-15
FI942906A0 (fi) 1994-06-17
MX9207374A (es) 1993-07-01
CZ283361B6 (cs) 1998-03-18
JP2950617B2 (ja) 1999-09-20
DK0618807T3 (da) 2003-03-03
EP1197222B1 (de) 2007-08-01
SK75494A3 (en) 1995-03-08
EP1197222A2 (de) 2002-04-17
SK279641B6 (sk) 1999-01-11
HU9401832D0 (en) 1994-09-28
NO942300L (no) 1994-08-19
ES2185625T3 (es) 2003-05-01

Similar Documents

Publication Publication Date Title
DE10399015I1 (de) Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
DE69228704D1 (de) Stabilisierte pharmazeutische formulierung, die wachstumshormon und asparagin enthält
CA2037884A1 (en) Stabilized gonadotropin containing preparations
ATE214614T1 (de) Ein wachstumshormon und isoleucin enthaltende pharmazeutische formulierung
DE69524965D1 (de) Wachstumshormon und valin enthaltende arzneimittel
DE69313444D1 (de) IL-6 ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN stabilisiert mit einem nicht-reduzierenden Zucker
ES2139081T3 (es) Composiciones farmaceuticas que contienen la hormona humana del crecimiento.
IL115592A (en) Stabilized pharmaceutical formulation comprising a growth hormone and leucine
HUP9802286A2 (hu) Stabilizált gyógyszerkészítmény amely valamely növekedési hormont és legalább egy bázikus aminosavmaradékot és legalább egy savas aminosav maradékot tartalmazó peptidet foglal magában

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0618807

Country of ref document: EP